Is WuXi AppTec's Buyback Campaign Working Amid Mounting US Pressure?

WuXi AppTec launched a HK$1.26 billion buyback campaign to shore up its share price amid sector weakness and geopolitical headwinds. However, the company's stock fell over 5% after the U.S. Department of Defense designated it as a military-linked company on June 8, raising compliance concerns for its major multinational clients. Despite solid fundamentals with a 23.6% year-on-year increase in order backlog, the company faces significant policy uncertainty that may be overpriced into its current valuation.

06/11/2026, 9:07 AM • Benzinga

Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

Zenas BioPharma reported Q1 2026 financial results with cash position of $718.5M and extended runway through Q2 2029. The company advanced obexelimab toward FDA/EMA submissions for IgG4-RD treatment, completed enrollment in the Phase 2 SunStone SLE trial with results expected Q4 2026, initiated Phase 1 testing of oral IL-17 inhibitor ZB021, and continued Phase 3 trials for orelabrutinib in multiple sclerosis. R&D expenses increased to $60.4M from $34.9M year-over-year, and net loss widened to $81.0M from $33.6M, primarily due to increased clinical trial and manufacturing costs.

05/13/2026, 6:00 AM • GlobeNewswire

Pharmaceutical Contract Development and Manufacturing Organization (CDMO) for Formulations Market Research Report 2026: Opportunities, Trends, Competitive Landscape, Strategies, Forecasts 2020-2035

The pharmaceutical Contract Development and Manufacturing Organization (CDMO) for formulations market is experiencing rapid growth with a projected CAGR of 10.6% through 2030. Growth drivers include increased outsourcing of peptide API manufacturing, expansion of GMP-grade production, and advancements in biologic formulation platforms. Strategic acquisitions and innovations in high-concentration protein formulations are reshaping the competitive landscape.

04/30/2026, 12:00 PM • GlobeNewswire

Global Biopharmaceutical CMO Market Projected to Reach USD 76.20 Billion by 2035, Fueled by Rising Biologics Demand and Expanding Outsourcing Strategies – SNS Insider

The global biopharmaceutical contract manufacturing organization (CMO) market is estimated at USD 21.16 billion in 2025 and is projected to grow to USD 76.20 billion by 2035, with a CAGR of 13.67%. Growth is driven by rising biologics demand, capacity constraints among innovator firms, and increased outsourcing strategies by pharmaceutical companies. North America holds the largest market share at 43.67%, while Asia Pacific shows the fastest growth at 15.23% CAGR.

02/24/2026, 4:00 AM • GlobeNewswire

Antibody Optimization Service (Affinity Maturation, Humanization, Phage Display, AI-based Computational Optimization) Market Trends Analysis and Growth Forecast Report 2025-2033

The global antibody optimization service market is projected to grow from USD 1.36 billion in 2024 to USD 2.87 billion by 2033, with a CAGR of 8.81%. Growth is driven by rising prevalence of complex diseases, increased R&D investments in biologics, and advancements in computational modeling and protein engineering technologies.

01/21/2026, 4:38 AM • GlobeNewswire

Single-Use Bioprocessing Market Projected to Reach US$ 122.92 Billion by 2035, Supported by Expansion of Biomanufacturing Capacity Says Astute Analytica

The global single-use bioprocessing market is expected to grow from USD 30.12 billion in 2025 to USD 122.92 billion by 2035 at a CAGR of 15.1%. Driven by technological breakthroughs in bioreactor scalability (up to 6,000L), 40-50% CAPEX reductions, and FDA approvals of 16 single-use-manufactured biologics in 2024, the market is becoming the standard for commercial biomanufacturing. Major players are expanding capacity significantly, with CDMOs like WuXi Biologics managing substantial backlogs.

01/20/2026, 12:38 PM • GlobeNewswire

Continuous Bioprocessing Market Set to Surpass Valuation of US$ 2,331.98 Million By 2035 | Astute Analytica

The global continuous bioprocessing market is projected to grow from USD 319.77 million in 2025 to USD 2,331.98 million by 2035 at a CAGR of 21.98%. Driven by demand for biosimilars and complex biologics, manufacturers are shifting from traditional fed-batch to continuous methods, achieving 50% cost reductions and significant sustainability improvements. North America leads with 39% market share, while Asia Pacific rapidly expands capacity. Major pharmaceutical and biotech companies are deploying billions in capital investments to modernize manufacturing infrastructure.

01/16/2026, 12:38 PM • GlobeNewswire

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

Akari Therapeutics announced progress in 2025 and outlined its path toward clinical transition in 2026. The company established a manufacturing partnership with WuXi Biologics and initiated pre-filing activities, with plans to launch its First-in-Human clinical trial by late 2026/early 2027. The company's lead candidate AKTX-101 is an ADC targeting Trop2 with a novel PH1 spliceosome-modulating payload designed to deliver dual mechanisms of action: direct tumor cytotoxicity and immune activation.

01/09/2026, 9:00 AM • GlobeNewswire

Vaccine Development Company Landscape Report 2025: Recent Expansions, Partnerships and Collaborations, Big Pharma Initiatives and Cost Price Analysis

The global vaccine development market is experiencing significant growth, with an estimated 7 billion doses produced in 2024 and expected 8 billion doses in 2025, driven by innovative technologies like mRNA vaccines and expansions in the Asia-Pacific region.

12/02/2025, 4:37 AM • GlobeNewswire

GMP Drug Substance Market to Reach USD 4.64 Billion by 2034, Growing at 6.14% CAGR

The global GMP drug substance market is projected to grow from $2.71 billion in 2025 to $4.64 billion by 2034, with a 6.14% CAGR. North America dominates the market, driven by advanced manufacturing infrastructure and increasing demand for biologics and complex therapies.

11/21/2025, 9:00 AM • GlobeNewswire

Contract Manufacturing & Design Services Market Size to Hit USD 1441.89 Billion by 2032, at 9.8% CAGR | SNS Insider

The Contract Manufacturing and Design Services Market is projected to grow from USD 621.36 billion in 2024 to USD 1441.89 billion by 2032, driven by technological innovations like IoT, AI, and Industry 4.0, with Asia Pacific leading market expansion.

10/10/2025, 6:00 AM • GlobeNewswire